Short answer: Announced peptide CDMO expansions can change the supply landscape, but an announced reactor is not the same as capacity that is qualified, available and suitable for a specific sequence. Ask when a line can accept a project, which purification and analytical steps are in scope, and how the supplier will link samples to the proposed commercial lot. This article is a B2B sourcing briefing, not an offer of first-in-human clinical manufacturing.
Peptide outsourcing is moving from specialist, low-volume programs toward larger commercial campaigns. That shift creates opportunity for buyers, but an announced reactor is not the same as capacity that is qualified, available and suitable for a specific sequence. Procurement teams should ask when a line can accept a project, which purification and analytical steps are in scope, and how the supplier will link samples to the proposed commercial lot.
A forecast, not a purchase order
Visiongain’s September 2026 forecast estimates the peptide contract manufacturing market at US$3.89 billion in 2026 and US$12.88 billion by 2036. This is one analyst’s forecast, not a measure of booked production. Its useful signal is the scale of expected demand for synthesis, purification, formulation and testing capacity.
Where companies are investing
CordenPharma says its Muttenz, Switzerland project will add more than 5,000 L of solid-phase peptide synthesis (SPPS) reactor capacity, with commercial activity planned for the first half of 2028. Its Colorado expansion is intended to lift SPPS reactor capacity above 42,000 L by 2028. SK pharmteco announced a US$260 million Sejong, South Korea facility covering small-molecule and peptide production. PolyPeptide began production at its new large-scale SPPS facility in Belgium in December 2024.
Those statements describe company plans and operating milestones. They do not establish that every line is available for every buyer or that a proposed lot meets the buyer’s specifications.
What to put in a capacity request
- Material identity: sequence or agreed reference, salt or counterion, and intended material form.
- Commercial presentation: target quantity, unit of measure, pack format and forecast cadence.
- Quality scope: identity, purity, content, impurity and stability requirements relevant to the program.
- Timing: sample date, qualification window, proposed production slot and delivery location.
- Evidence: which records will be supplied for the sample and the offered batch, and how the two are linked.
A multi-region supply plan can be useful, but each source still needs its own identity, quality and documentation review. Compare qualified capacity and the agreed deliverables before comparing headline reactor size or price per gram.
Sources
Visiongain market forecast, September 2026; CordenPharma capacity announcement; SK pharmteco expansion announcement; PolyPeptide production announcement.
Industry and procurement briefing. Company plans and market forecasts may change; confirm current capacity and specifications with the named supplier.
What this article is not
This is a B2B sourcing briefing, not an offer of first-in-human clinical manufacturing.
API sourcing · OEM discussion · Supplier qualification · Independent testing · Quality and COA library
Frequently asked questions
Does an announced CDMO expansion mean capacity is available for my project?
No. Company plans and operating milestones do not establish that every line is available for every buyer, or that a proposed lot meets the buyer's specifications. Ask when a line can accept the project and what is in scope.
Is this article an offer of first-in-human or injectable clinical manufacturing?
No. It is a sourcing briefing for professional buyers. It is not an offer of first-in-human clinical manufacturing and not a purchase commitment.
What should a capacity request include?
Material identity (sequence or agreed reference, salt or counterion, form); commercial presentation (quantity, pack, forecast); quality scope (identity, purity, content, impurity and stability requirements relevant to the program); timing; and which records will link the sample to the offered batch.
How does First1BioLab use this topic with buyers?
The page invites buyers to share a proposed material, scale, timeline and analytical scope for an OEM discussion. Confirm current capacity and specifications with the named supplier; forecasts may change.